medRxiv
Gantenerumab reduces brain amyloid-β proteoforms: Biochemical evaluation in dominantly inherited Alzheimer disease
Preprint: non-randomised trial in peopleAlzheimer's disease
Papers by David B. Clifford
8 results
- AAIC 2025 Abstract
Baseline Participant Characteristics in the DIAN‐TU‐001 Trial
Trial in peoplePopulations - AAIC 2025 Abstract
DIAN‐TU‐001 Trial (Tau NexGen) Rationale and Enrollment Experience
Trial in peopleInterventions
- AAIC 2025 Abstract
Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial
Trial in peopleInterventions